CASIF
CASI Pharmaceuticals, Inc.Company with tickers: CASIF
CIK
1962738
CUSIP
G1933S101
Shares Outstanding
20,555,873
13F Activity (30d)
2 filings
2 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $20,712,000 | USD | 2025-12-31 | 20-F | 2026-05-15 |
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | $10,076,000 | USD | 2025-12-31 | 20-F | 2026-05-15 |
| Operating Expenses | — | ||||
| Research & Development | $6,308,000 | USD | 2025-12-31 | 20-F | 2026-05-15 |
| Operating Income | $-45,007,000 | USD | 2025-12-31 | 20-F | 2026-05-15 |
| Net Income | $-48,058,000 | USD | 2025-12-31 | 20-F | 2026-05-15 |
| EPS (Basic) | $-2.59 | USD/shares | 2025-12-31 | 20-F | 2026-05-15 |
| EPS (Diluted) | $-2.59 | USD/shares | 2025-12-31 | 20-F | 2026-05-15 |